SCOPUS 정보 검색 플랫폼

Annals of Allergy, Asthma and Immunology

Volumn 100, Issue 6, 2008, Pages 621-622

Severe generalized exanthema due to etanercept given for severe plaque psoriasis

(3) Gonzalo Garijo, M Angeles a Pérez Calderón, Remedios a Fernández Durán, Diego De Argila b

a HOSPITAL INFANTA CRISTINA (Spain)

b HOSPITAL UNIVERSITARIO DE LA PRINCESA (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; INFLIXIMAB;

ADULT; ARTHRALGIA; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LETTER; MALAISE; PATCH TEST; PRICK TEST; PRIORITY JOURNAL; PSORIASIS VULGARIS; RASH; SYMPTOM; TREATMENT OUTCOME;

EID: 45149122769 PISSN: 10811206 EISSN: None Source Type: Journal
DOI: 10.1016/S1081-1206(10)60067-1 Document Type: Letter

Times cited : (5)

References (8)

1
- 85031390945
- Accessed December 13, 2007
- Enbrel (etanercept) label information from the FDA. http://www.fda.gov/ cder/foi/label/2007/103795s53221bl.pdf. Accessed December 13, 2007.
- Enbrel (etanercept) label information from the FDA

2
- 34250761386
- Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
- Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719-726.
- (2007) Arch Dermatol , vol.143 , pp. 719-726
- Tyring, S.¹ Gordon, K.B.² Poulin, Y.³

3
- 34347228129
- Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: An updated review
- Romero-Maté A, García-Donoso C, Córdoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol. 2007;8:143-155.
- (2007) Am J Clin Dermatol , vol.8 , pp. 143-155
- Romero-Maté, A.¹ García-Donoso, C.² Córdoba-Guijarro, S.³

4
- 34247368071
- Two years of experience with etanercept in recalcitrant psoriasis
- Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol. 2007;156:1010-1014.
- (2007) Br J Dermatol , vol.156 , pp. 1010-1014
- Ahmad, K.¹ Rogers, S.²

5
- 26244458988
- Cutaneous adverse events of biological therapy for psoriasis: Review of the literature
- Thielen AM, Kuenzli S, Saurat JH. Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology. 2005;211:209-217.
- (2005) Dermatology , vol.211 , pp. 209-217
- Thielen, A.M.¹ Kuenzli, S.² Saurat, J.H.³

6
- 0036715313
- Cutaneous drug eruption to infliximab: Report of 4 cases with an interface dermatitis pattern
- Vergara G, Silvestre JF, Betlloch I, et al. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol. 2002;138:1258-1259.
- (2002) Arch Dermatol , vol.138 , pp. 1258-1259
- Vergara, G.¹ Silvestre, J.F.² Betlloch, I.³

7
- 0036101615
- Etanercept and infliximab associated with cutaneous vasculitis
- McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford). 2002;41:116-117.
- (2002) Rheumatology (Oxford) , vol.41 , pp. 116-117
- McCain, M.E.¹ Quinet, R.J.² Davis, W.E.³

8
- 11144310030
- Eczematous drug eruption after infliximab
- Dumont-Berset M, Laffitte E, Gerber C, Dudler J, Panizzon RG. Eczematous drug eruption after infliximab. Br J Dermatol. 2004;151:1272-1273.
- (2004) Br J Dermatol , vol.151 , pp. 1272-1273
- Dumont-Berset, M.¹ Laffitte, E.² Gerber, C.³ Dudler, J.⁴ Panizzon, R.G.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.